Cyclo Therapeutics Inc (CYTH) Stock Price, Quote & News

DottoreMK May. 9 at 4:16 PM

$CYTH

0 · Reply

Miko_Vakilla Apr. 7 at 8:39 PM

$CYTH Form 15! $2.15 here we come. Let's go Mo!

0 · Reply

GDS_investing Apr. 7 at 6:06 PM

$RFL money on the floor add here today for 5$+ $CYTH

0 · Reply

StreetSlap Apr. 6 at 7:03 AM

$ANVS $CYTH $CEIN $IMUX $PTPI Lol Nah...great retail hunters, great scammers, but Maria just set the bar to a new low 🐍💃🏻

1 · Reply

ForestFoxes Apr. 6 at 12:27 AM

$ANVS $CYTH $CEIN $IMUX $PTPI @StreetSlap🤯 ⁿᵒ ʷᵃʸ ... 🤨 ᵃʳᵉ ʸᵒᵘ ᵗᵉˡˡᶦⁿᵍ ᵐᵉ ᵗʰᵃᵗ ᵗʰᵒˢᵉ ᶜᴱᴼˢ ... ᵃˡˢᵒ ʰᵉˡᵈ ᵃ ᴾᵃᵗᶦᵉⁿᵗˢ' ᴸᶦᵛᵉ ᶠᵒʳᵘᵐ and, told patients and their families to "BUY Stock!" and "That's the ONLY out of it!" 💔 Did those other CEOs also use fiery language in their chat with patients and families with references to Hell repeated??? 🔥🐍😈🔥

1 · Reply

StreetSlap Apr. 5 at 9:56 PM

$ANVS Golden rule ! Saw that so many times...$CYTH (Scott Fine) $CEIN (James Doris) $IMUX (Daniel Vitt) $PTPI (Fady Boctor) just to name a few

0 · Reply

JoeLogan Apr. 4 at 4:55 PM

$CYTH My man Scott and fam after receiving donations from baggies all years round.

0 · Reply

Love_To_Learn Mar. 31 at 7:10 PM

$ICCT code change adding $CYTH 1.52***** super filler created 2024!

2 · Reply

MK2020 Mar. 30 at 9:58 PM

$CYTH What I also see as important, but which is not currently in focus, is that if the NPC mediament works, this is also very positive for the Alzheimer's study.

0 · Reply

Looserman Mar. 30 at 6:46 AM

$CYTH How many shares will I get for my 1,200 shares ?

2 · Reply

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

RFL

Feb 7, 2025, 8:05 AM EST - 4 months ago

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

Jan 14, 2025, 8:05 AM EST - 5 months ago

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

Dec 20, 2024, 12:15 PM EST - 6 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders

SKGR

Nov 21, 2024, 4:13 AM EST - 7 months ago

Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio

Nov 14, 2024, 8:05 AM EST - 7 months ago

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 5, 2024, 9:05 AM EDT - 10 months ago

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Aug 22, 2024, 10:19 AM EDT - 10 months ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

RFL

Aug 22, 2024, 6:50 AM EDT - 10 months ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

RFL

Aug 15, 2024, 9:00 AM EDT - 10 months ago

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 29, 2024, 9:05 AM EDT - 11 months ago

Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office

Jun 25, 2024, 9:25 AM EDT - 1 year ago

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024

May 30, 2024, 9:00 AM EDT - 1 year ago

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

May 16, 2024, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Mar 18, 2024, 9:05 AM EDT - 1 year ago

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 14, 2024, 9:34 AM EDT - 1 year ago

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

Jan 29, 2024, 9:15 AM EST - 1 year ago

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

Dec 27, 2023, 4:15 PM EST - 1 year ago

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Dec 18, 2023, 9:15 AM EST - 1 year ago

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Nov 28, 2023, 5:19 PM EST - 1 year ago

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Nov 21, 2023, 8:05 AM EST - 1 year ago

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Nov 15, 2023, 8:05 AM EST - 1 year ago

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Oct 5, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Sep 21, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Aug 15, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

RFL

Jun 29, 2023, 1:32 PM EDT - 2 years ago

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Jun 12, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's Disease

Jun 5, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

RFL

May 15, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

May 2, 2023, 8:12 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

RFL

Apr 21, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 20, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Jan 11, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Jan 10, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Jan 9, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Jan 4, 2023, 4:05 PM EST - 2 years ago

Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 4, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Dec 30, 2022, 8:00 AM EST - 2 years ago

Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Nov 11, 2022, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements

Oct 18, 2022, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Oct 4, 2022, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Sep 28, 2022, 2:02 PM EDT - 2 years ago

Cyclo Therapeutics Provides Business Update

Sep 7, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 16, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 8, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics to Present at the China NPC Association Meeting

Jul 21, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

DottoreMK May. 9 at 4:16 PM

$CYTH

0 · Reply

Miko_Vakilla Apr. 7 at 8:39 PM

$CYTH Form 15! $2.15 here we come. Let's go Mo!

0 · Reply

GDS_investing Apr. 7 at 6:06 PM

$RFL money on the floor add here today for 5$+ $CYTH

0 · Reply

StreetSlap Apr. 6 at 7:03 AM

$ANVS $CYTH $CEIN $IMUX $PTPI Lol Nah...great retail hunters, great scammers, but Maria just set the bar to a new low 🐍💃🏻

1 · Reply

ForestFoxes Apr. 6 at 12:27 AM

1 · Reply

StreetSlap Apr. 5 at 9:56 PM

$ANVS Golden rule ! Saw that so many times...$CYTH (Scott Fine) $CEIN (James Doris) $IMUX (Daniel Vitt) $PTPI (Fady Boctor) just to name a few

0 · Reply

JoeLogan Apr. 4 at 4:55 PM

$CYTH My man Scott and fam after receiving donations from baggies all years round.

0 · Reply

Love_To_Learn Mar. 31 at 7:10 PM

$ICCT code change adding $CYTH 1.52***** super filler created 2024!

2 · Reply

MK2020 Mar. 30 at 9:58 PM

$CYTH What I also see as important, but which is not currently in focus, is that if the NPC mediament works, this is also very positive for the Alzheimer's study.

0 · Reply

Looserman Mar. 30 at 6:46 AM

$CYTH How many shares will I get for my 1,200 shares ?

2 · Reply

LC_Investor Mar. 28 at 8:06 PM

$CYTH

0 · Reply

northmark1 Mar. 28 at 11:55 AM

$CYTH Well I got Ripped off. Only got one share of RFL for everyone of my Cyth shares. Bullshit Deal. Was supposed to be shares of RFL for every Cyth.

2 · Reply

Hickory68 Mar. 27 at 3:16 PM

$CYTH Still showing I own $CYTH when will my stocks convert?

1 · Reply

Miko_Vakilla Mar. 27 at 2:43 PM

$CYTH The Fine family made a killing on this one. Stripped the value straight out of the hands of the equity owners. @M_W_T

0 · Reply

Curate Mar. 27 at 1:35 PM

$CYTH my shares have converted. In with over 5000 of $RFL shares at a ridiculous average price each. Will try to dollar costs average this down in time cause I’m still holding out on this molecule!

4 · Reply

CaseOfTheYips1 Mar. 27 at 1:34 PM

$CYTH will be my last posts here. Shares converted and I’m now looking at $10.78 to break even… still going to grandma’s house, just had to change vehicles… 🤞🤞🥃

3 · Reply

yilayan1980 Mar. 27 at 10:06 AM

$CYTH what happens if you own shares ??

1 · Reply

marinax Mar. 27 at 7:10 AM

$CYTH so after converting to RFL, you all will buy more RFl shares to bring average down or what ?? second when final data will be released? anybody knows exact deadline ?

0 · Reply

Mikeynumbers Mar. 27 at 2:32 AM

$CYTH I just got back from the SAVA funeral today. It was well attended by the tendies club. Lots of tears.

0 · Reply

Roadtofruition Mar. 26 at 8:10 PM

$CYTH $RFL As of now, Markus is the only one with original ties to Cyclo that has a seat on the board.

2 · Reply

northmark1 Mar. 26 at 6:43 PM

$CYTH RFL is only paying .35 per Share. People are losing their shit!

2 · Reply

Pizzino Mar. 26 at 3:42 PM

$CYTH Let’s see what Scott masterminded for the company. I still feel he has put together a winning plan 🤞🏻

0 · Reply

Market Cap	23.72M
Revenue (ttm)	1.08M
Net Income (ttm)	-20.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,857.41%
Debt to Equity Ratio	0.00

Volume	188,200
Avg Vol	1,832,044
Day's Range	N/A - N/A
Shares Out	32.92M
Stochastic %K	74%
Beta	-0.57
Analysts	Sell
Price Target	$0.95